The CSI Innovative Drug Industry Index jumped 3.04% on March 24, 2026, lifting the Jiànxìn Innovative Drug ETF (159835) alongside it. Leading the rally were Dizhe Medicine (+9.09%), WuXi AppTec (+6.71%) and Zejing Pharmaceutical (+6.70%), with Junshi Biology, Yifan Medicine and others also posting gains. Two breakthrough announcements are fueling the optimism. On March 22, Dizhe Medicine reported that its self‑developed lung‑cancer pill, Shuwozhe (suvoitinib), met its primary endpoint in the international Phase III “Wukong 28” trial, showing strong results for patients with EGFR exon‑20 insertion mutations. The next day, Rongchang Biology secured approval for its vedicitumab injection (Aidixi) to treat HER2‑low breast cancer with liver metastasis, marking the drug’s fourth approved indication in China. The company also struck a record‑breaking $5.6 billion partnership with AbbVie to license its RC148 bispecific antibody outside Greater China. Analysts at Zhongyou Securities say the sector is on a volatile but upward trajectory, with solid clinical data and expanding overseas deals bolstering confidence. The upcoming 2026 AACR Annual Meeting in San Diego (April 17‑22) will showcase more Chinese innovations, underscoring the industry’s growing global footprint. The ETF mirrors the performance of up to 50 listed firms focused on cutting‑edge drug R&D, offering investors a direct play on China’s rising biotech wave.
Read more